Companies › SillaJen
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BAL0891 Dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) | TTK, PLK1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05768932 | BAL0891 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.